INTRAVENOUS GP531, AN ADENOSINE REGULATING AGENT, IMPROVES LEFT VENTRICULAR DIASTOLIC FUNCTION IN DOGS WITH CHRONIC HEART FAILURE  by Sabbah, Hani N. et al.
A38.E366
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
INTRAVENOUS GP531, AN ADENOSINE REGULATING AGENT, IMPROVES LEFT VENTRICULAR DIASTOLIC 
FUNCTION IN DOGS WITH CHRONIC HEART FAILURE
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Heart Failure with Preserved Ejection Fraction and Diastolic Function
Abstract Category: Myocardial Function/Heart Failure--Clinical Pharmacological Treatment
Presentation Number: 1236-79
Authors: Hani N. Sabbah, Mengjun Wang, Itamar Ilsar, Ramesh C. Gupta, Alice Jiang, Michael S. Sabbah, Kaitlin Dye, Henry Ford Hospital, Detroit, MI
Background: Adenosine Regulating Agents (ARAs) increase local endogenous adenosine release during episodes of cellular stress in which ATP 
breakdown exceeds ATP synthesis as in myocardial ischemia or hypoxia. We showed that GP531, an ARA, improves LV systolic function in dogs with 
heart failure (HF). This study examined the effects of i.v. GP531 on LV diastolic function in dogs with HF.
Methods: Six dogs with coronary microembolization-induced HF were studied. Dogs underwent 2 acute 6-hour studies performed at random one 
week apart. GP531 was infused in one study (10 μg/kg/min) and saline (control) in the other. LV EF, end-diastolic (ED) pressure (EDP), ED wall 
stress (EDWS), mitral inflow velocity ratios PE/PA and Ei/Ai and deceleration time (DCT) were measured at baseline and hourly thereafter. The slope 
of the ED pressure-volume relationship (EDPVR) was measured (conductance catheter) at baseline and 6 hours.
Results: Compared to baseline, GP531 increased EF, PE/PA, Ei/Ai and DCT and decreased EDV, EDP and EDWS (Table). GP531 decreased the slope 
of the EDPVR consistent with improved load-independent active LV relaxation but the decline was not statistically significance. Saline infusion had 
no effect on any of the parameters.
Conclusions: In dogs with advanced HF, acute i.v. GP531 improves LV diastolic function without eliciting chronotropic effects, hypotension or de-
novo arrhythmias. The results favor continued development of GP531 for the treatment of acute HF syndromes. 
Baseline and 6 Hour Results (Mean ± SEM)
Control GP531
Baseline 6 Hours Baseline 6 Hours
EF (%) 27 ± 1 27 ± 1 27 ± 1 34 ± 1*
EDP (mmHg) 14 ±1 13 ± 1 13 ± 1 10 ± 1*
PE/PA 1.52 ± 0.04 1.49 ± 0.06 1.49 ± 0.06 2.25 ± 0.06*
Ei/Ai 1.47 ± 0.09 1.51 ± 0.06 1.41 ± 0.10 2.77 ± 0.23*
DCT (msec) 91 ± 3 95 ± 4 90 ± 4 118 ± 4*
EDWS (gm/cm2) 59 ± 5 52 ± 4 56 ± 6 41 ± 7*
Slope of ESPVR (mmHg/
ml)
0.41 ± 0.07 0.38 ± 0.06 0.34 ± 0.03 0.29 ± 0.02
*=p<0.05 vs. Baseline
